CN1569158A - Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process - Google Patents
Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process Download PDFInfo
- Publication number
- CN1569158A CN1569158A CN 200410022510 CN200410022510A CN1569158A CN 1569158 A CN1569158 A CN 1569158A CN 200410022510 CN200410022510 CN 200410022510 CN 200410022510 A CN200410022510 A CN 200410022510A CN 1569158 A CN1569158 A CN 1569158A
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- injection
- herba erigerontis
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process, which is prepared mainly from herb of shortcape fleabane and ginkgo.
Description
Technical field: the present invention is a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof, belongs to technical field of Chinese medicine.
Technical background: cardiovascular and cerebrovascular disease such as coronary heart disease, cerebral thrombosis, alzheimer disease etc. all are one of the most common and diseases that harm is maximum in the world today, have become human mortality's one of the main reasons in many countries; According to investigations, sickness rate in recent years has and increases trend year by year, and in, young patient constantly increases, ischemic cardiovascular and cerebral vascular disease has become commonly encountered diseases, the frequently-occurring disease of harm China people ' s health; Prevent and treat purpose in order to reach, a large amount of research has been done by many inventors and medicine enterprise, and the product of some treatments also is provided; As: number of patent application is: 00112841.8, name is called " a kind of Chinese traditional compound medicine and production method thereof for the treatment of cerebral arteriosclerosis " and number of patent application is: 02134144, name is called " Xinmai dripping pill " and is the medicine for the treatment of this respect disease; But first kind of product used MANSHANXIANG, and MANSHANXIANG is slightly poisonous, and the absurd person of deficiency of YIN fire avoids clothes, and taste is bad, the patient is unwilling accepts; Second kind of product used Radix Salviae Miltiorrhizae, Borneolum Syntheticum, the two is the high Chinese medicine of bibliographical information anaphylaxis occurrence frequency, the effective ingredient TANSHINONES of Radix Salviae Miltiorrhizae is that the chemical constituent with biochemical activity gene can become hapten, Borneolum Syntheticum not only may cause allergy, the anemia of pregnant woman also should not use, and stomach there is zest, obviously aggravation stomachache; So have certain problem on their the suitable crowd; In addition, because it is numerous to suffer from the patient of similar disease, so need provide more to market, obvious results, the treatment medicine of being free from side effects.In view of such circumstances, seek that a kind of medical material compatibility is simple, therapeutic effect is desirable, does not have toxic and side effects, the thing that preparation technology's rational and effective medicine preparation has become people to be badly in need of solving.
Summary of the invention: the objective of the invention is to: a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof is provided; The present invention is directed to prior art, according to cardiovascular and cerebrovascular disease such as coronary heart disease, cerebral thrombosis, alzheimer disease etc. all contract because of blood vessel is narrow, reason such as blood flow minimizing causes the diseases induced principle of blood supply insufficiency, adopts Herba Erigerontis and Semen Ginkgo compatibility to make preparation; It has activating blood circulation to dissipate blood stasis, TONGMAI SHULUO, improves blood circulation and metabolism.For example coronary heart disease is that coronary atherosclerosis causes myocardial ischemia, anoxia and the heart disease that causes, and two medicines share, and can play to improve the myocardial metabolism effect, increase coronary flow, and the blood that improves cardiac muscle is provided with the effect of allevating angina pectoris.The present invention has curative effect preferably for treating cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, arrhythmia, cerebral thrombosis, alzheimer disease etc.And the present invention is pure Chinese medicinal preparation, but the little patients life-time service of its untoward reaction.
The present invention constitutes like this: calculate according to components by weight percent, it mainly is made for 99～1 parts by 1～99 part of Herba Erigerontis and Semen Ginkgo, or corresponding weight fraction Herba Erigerontis extract that obtains after extracting and the Semen Ginkgo extrac that corresponding weight fraction obtains after extraction are made.Specifically: calculate according to components by weight percent, it mainly is made for 80～20 parts by 20～80 parts of Herba Erigerontiss and Semen Ginkgo, or corresponding weight fraction Herba Erigerontis extract that obtains after extracting and the Semen Ginkgo extrac that corresponding weight fraction obtains after extraction are made.Say accurately: calculate according to components by weight percent, it is made for 50 parts with Semen Ginkgo by 50 parts of Herba Erigerontiss, or corresponding weight fraction Herba Erigerontis extract that obtains after extracting and the Semen Ginkgo extrac that corresponding weight fraction obtains after extraction are made.Preparation of the present invention is: injection, comprising: injection, powder pin, freeze-dried powder, tablet, capsule, soft capsule, pellet, granule, pill, powder, drop pill, slow releasing preparation, controlled release preparation, oral liquid, gel, soft extract, extractum and membrane.Reasonable preparation is: injection, comprising: injection, powder pin, freeze-dried powder, tablet, capsule, granule, drop pill.
Preparation method provided by the invention is: get Herba Erigerontis, decoct with water, merge decocting liquid, filter, concentrating under reduced pressure adds ethanol precipitation, leaves standstill, and the clear liquid decompression recycling ethanol is re-refined, concentrated, and crushed after being dried promptly gets Herba Erigerontis extract; Get Semen Ginkgo, be ground into coarse powder, alcohol reflux is collected extracting solution, reclaims ethanol, re-refine, concentrate, after the drying again with the Herba Erigerontis extract mix homogeneously, make different preparations then respectively.Say that accurately the concrete preparation method of the present invention is: get Herba Erigerontis, decoct with water 1～3 time, each 0.5～5 hour, merge decocting liquid, filter, concentrating under reduced pressure adds ethanol precipitation, leaves standstill, supernatant decompression recycling ethanol 6N HCl is adjusted to pH about 2.5, with the extraction of ethyl acetate-ethanol (9: 1) mixed solution, extract concentrating under reduced pressure, remove ethyl acetate, drying is ground into the above fine powder of 60 orders, promptly gets Herba Erigerontis extract; Get Semen Ginkgo, be ground into coarse powder, make solvent with 70% ethanol, reflux, extract, 1～3 time after each 1～3 hour, reclaims ethanol, add water dissolution, refining with macroporous adsorbent resin, use 70% ethanol elution, collect effluent to colourless, effluent is through decompression recycling ethanol, concentrated, dry, pulverizing again with the Herba Erigerontis extract mix homogeneously, are made different preparations respectively then.
Capsule in the preparation of the present invention prepares like this: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add 2% methylcellulose, add the moistening back of water and granulate, mixing incapsulates, promptly.
Tablet in the preparation of the present invention prepares like this: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add methylcellulose 2%, it is moistening to add water, makes granule, and drying adds 3% carboxymethyl starch sodium, tabletting, and coating, promptly.
Granule in the preparation of the present invention prepares like this: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add 2% low-substituted hydroxypropyl cellulose, it is moistening to add water, makes granule, drying, promptly.
Injection in the preparation of the present invention prepares like this: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add the dissolving of injection water, regulate pH value to 6.0～6.5 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled, filter, add an amount of sodium chloride for injection and make it dissolving; Add water for injection again to certain volume, filtration, fill, sterilization, promptly.
Injection in the preparation of the present invention prepares like this: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add the dissolving of injection water, regulate pH value to 6.0～6.5 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled, filter, add an amount of sodium chloride for injection and make it dissolving; Add sterile water for injection to full dose, packing after vacuum lyophilization or aseptic filtration or the spray drying, sealing is promptly.
Compared with prior art, Herba Erigerontis hardship cold in nature, little, Gan Wen, suffering, tepor, have functions such as expelling cold and relieving exterior syndrome, relaxing muscles and tendons to promote blood circulation, pain relieving removing food stagnancy, it has blood vessel dilating, decreased heart rate, reduction myocardium keto consumption, reduces Peripheral resistance, promotes effects such as side Zhi Xunhuan, blood viscosity lowering; Folium Ginkgo can be expanded hat tremulous pulse and cerebrovascular, increases the blood flow of heart and brain, improves the heart and brain metabolism, recovers normal function; Blood viscosity lowering is promoted erythrocyte deformability, microcirculation improvement; Have and prevent and treat platelet aggregation efficiently, microthrombusis and lipid metabolic disorder effect.The present invention adopts Herba Erigerontis and Semen Ginkgo compatibility to make preparation; Have activating blood circulation to dissipate blood stasis, TONGMAI SHULUO, improve blood circulation and metabolism, two medicines share, and can play and improve myocardial metabolism effect, increase coronary flow, and the blood that improves cardiac muscle is provided with the effect of allevating angina pectoris; The present invention has curative effect preferably for treating cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, arrhythmia, cerebral thrombosis, alzheimer disease etc., and do not select the medical materials such as MANSHANXIANG of anaphylactoid Radix Salviae Miltiorrhizae, Borneolum Syntheticum and untoward reaction for use, reached the purpose of invention.
The Herba Erigerontis that the present invention is selected, the ethyl acetate extraction rate of transform is lower after the water boiling and extraction, how to improve extraction yield and is directly connected to the product drug effect; The stability of Semen Ginkgo effective ingredient terpene lactones in injection also is urgent problem.The Herba Erigerontis composition mainly is a flavonoid glycosides, and its polarity is bigger, and ethyl acetate can not extract flavonoid glycoside fully, and the applicant thinks by experiment, adds a certain amount of ethanol and adjusts extract polarity, can improve extraction yield, has guaranteed the product curative effect; The applicant is determined by experiment the suitable pH value of injection, has guaranteed the stable of Semen Ginkgo effective ingredient terpene lactones, and the invention provides the detailed processing technology of several formulations, can be directly used in and instruct actual production.
The applicant has carried out a series of experiments, can prove the process conditions science that technology provided by the invention is reasonable, select; With the adjuvant effect ideal, effectively; The medicine that obtains has effective effect.
Experimental example 1: extraction process screening
Breviscapine can significantly increase the regional blood flow of intraluminal middle cerebral artery occlusion in rats infarct cerebral tissue, reduce cerebral infarct size, and the water peroxidase activity that ischemia is irritated in the cerebral tissue again has obvious inhibitory action, and the adhesion that promptly suppresses neutrophilic granulocyte in the ischemic tissue of brain is soaked into; Folium Ginkgo total flavones has the expansion meningeal arteries, the cerebral blood flow increasing amount, improve brain blood circulation function, improve the cardiac disorder that myocardial ischemia causes, suppress the platelet aggregation enzyme, antibiotic, antiviral, anticancer etc. is one of onset composition of this product, and extraction process directly influences the curative effect and the quality of product.
1. different influences of extracting solvent to the Ginkgo total flavones extraction ratio
Aqueous solvent 50% ethanol 70% ethanol 90% ethanol 50% acetone 70% acetone 50% methanol 70% first
Alcohol
Extraction ratio % 61.2 66.3 71.6 69.9 65.4 62.7 59.5 60.1
2. different influences of extracting solvent to breviscapine content
Aqueous solvent 30% ethanol 50% ethanol 65% ethanol 80% alcohol 95 % ethanol
Content % 6.82 6.03 6.65 6.39 5.48 2.37
3. ethyl acetate is to the influence of the extraction rate of transform of breviscapine
Extractant etoac ethyl acetate-ethanol ethyl acetate-ethanol ethyl acetate-second
Alcohol
(8∶2) (9∶1) (19∶1)
The extraction rate of transform 42% 40% 55% 45%
The result shows: extraction process of the present invention is rationally feasible, the effective component extraction rate height.
The screening of experimental example 2 moulding processs
Moulding process is directly connected to the character and the absorption in vivo utilization of product, is key technology of the present invention.
Average disintegration time: adopting changes the basket method, and lift disintegration tester, tablet or capsule are got 6 units, calculates the meansigma methods of passing through the screen cloth time fully.
Melting: get granule 10g, add 20 times of hot water, stirred 5 minutes, observe immediately.
(1) granule
1. adjuvant (consumption 3%) starch slurry arabic gum low-substituted hydroxypropyl cellulose
It is moist and dissolve the little tide of distortion granule that particle appearance is dissolved distortion and adhesion
Melting all dissolves t＜30s and all dissolves t＞30s and all dissolve t＜30s
The granulation complexity is easily granulated and the uniform particles difficulty is granulated, granule is crossed sticking easily the granulation and uniform particles
2. low-substituted hydroxypropyl cellulose is to the influence (n=3) of melting
Low-substituted hydroxypropyl cellulose consumption (%) 123
Melting all dissolves t＞30s and all dissolves t=20s and all dissolve=30s
(2) capsule
1. binder dosage % outward appearance disintegration (min)
Methylcellulose 5 granules little damp 30
Starch 5 is moist and dissolve distortion 45
Low-substituted hydroxypropyl cellulose 5 granules little damp 40
2. methylcellulose is to EFFECT OF CORK STOPPER (n=3)
Carboxymethyl starch sodium consumption (%) 12359
Disintegration (min) 40 20 28 31 30
(3) tablet: the screening of disintegrating agent
1. disintegrating agent consumption % outward appearance disintegration (min)
Dry starch 5 hardness are good, and bright and clean 70
Carboxymethyl starch sodium 5 hardness are good, glossy degree 30
5 loose 55 of low-substituted hydroxypropyl celluloses
2. the carboxymethyl starch sodium consumption is to EFFECT OF CORK STOPPER (n=3)
Carboxymethyl starch sodium consumption (%) 13579
Disintegration (min) 42 22 29 35 30
Experimental example 3 is the selection of injection pH value 1.: bilobalide is one of main pharmacodynamics composition in Folium Ginkgo extract and the preparation thereof, has anti-platelet activating factor, be the strong antagonist of platelet activating factor, have antiplatelet aggregation, Hangzhoupro thrombosis, prevent and treat atherosclerosis, anti-inflammatory and antiallergic.Under the condition of peracid or mistake alkali, the hydrolysis of ester all easily takes place in the terpene lactones that Semen Ginkgo contains, and we placed 3 months for 40 ℃ the injection of 6 kinds of different pH value, investigated its stability respectively.
0 month March
PH value color and luster clarity terpene lactones (mg/ml) color and luster clarity terpene lactones
(mg/ml)
5.5 yellowish aberration 2.52 yellowish-brown aberration 2.02
6.0 faint yellow clear and bright 2.50 faint yellow clear and bright 2.44
6.5 faint yellow clear and bright 2.41 faint yellow clear and bright 2.32
7.0 faint yellow clear and bright 2.49 yellowish-brown aberration 2.11
7.5 yellowish-brown clear and bright 2.55 yellowish-brown aberration 1.98
8.0 yellowish-brown aberration 2.57 yellowish-brown aberration 2.01
The result shows, adopts the selected prepared quality of the pharmaceutical preparations of adjuvant of the present invention stable, controlled; Make that the formed product of gained of the present invention is good.
2. the selection of powder pin pH value:
PH value clarity mouldability
5.5 difference is not good enough
6.0 bright molding
6.5 bright molding
7.0 difference is not good enough
7.5 difference is not good enough
8.0 difference is not good enough
Experimental example 4: to the influence of blood stasis model rabbit blood rheological characteristic
Test 1 group: the Xinmai dripping pill medicinal liquid; Test 2 groups: Herba Erigerontis, Semen Ginkgo, MANSHANXIANG medicinal liquid;
Test 3 groups: medicinal liquid of the present invention
36 of rabbit are divided into 6 groups at random, and 6 every group, ♀ ♂ half and half is respectively blank group, model control group, positive drug control group and tests 1,2,3 group.Each treated animal elder generation auricular vein is injected (iv) administration.Blank and model control group injecting normal saline (NS) 1ml/kg, positive drug group iv puerarin injection 30mg/kg (being made into 30mg/ml) with NS, experimental group is injected the medicinal liquid (being made into NF) of 0.25mg/ml respectively, dosage is 1ml/kg, two weeks of successive administration (14d), in administration the 2nd, 13d, except that the blank group, each rabbit is annotated 10% high molecular dextran 5ml/kg through auricular vein respectively, every day twice, causes blood stasis model.Behind the last administration h, inject 10% high molecular dextran 5ml/kg once more, behind the 15min, heart is taked fasting blood 6ml, carrying out hemorheology index detects, wherein platelet aggregation rate adopts turbidimetry for Determination: the rotary cone-plate viscosity apparatus mensuration of other employing LBY-N6A+ with LBY-NJ2 type platelet aggregation instrument.
To rabbit platelet aggregation and fibrinogenic influence (x ± s, n=6)
Group dosage (mg/kg) body weight (kg) platelet aggregation (%) Fibrinogen (g/L)
Blank group-2.31 ± 0.15 15.54 ± 2.46 2.53 ± 1.16
Model group-2.45 ± 0.08 38.27 ± 15.05 2.73 ± 1.41
Positive drug group 30 2.37 ± 0.11 12.74 ± 3.47 3.12 ± 1.83
Test 1 group 0.25 2.32 ± 0.15 14.86 ± 2.38 2.60 ± 0.94
Test 2 group 0.25 2.43 ± 0.13 14.28 ± 3.16 2.59 ± 1.85
Test 3 group 0.25 2.42 ± 0.12 13.97 ± 3.29 2.52 ± 2.15
The result shows, preparation good effect of the present invention, and do not select Radix Salviae Miltiorrhizae, Borneolum Syntheticum, MANSHANXIANG for use, do not have its untoward reaction that brings and anaphylaxis.
Clinical efficacy:
Physical data: all case is inpatient, diagnoses according to the angina pectoris diagnostic criteria.Total angina pectoris patient 60 examples adopt the table of random number method to be divided into treatment group 30 example and matched group 30 examples.Two groups of ordinary circumstances such as sex, age, the course of disease and angina pectoris typing have comparability.Exclusion standard: turn out to be chest pain person due to coronary heart disease myocardial infarction and severe heart neurosis, climacteric syndrome, cervical spondylosis etc. on inspection, merge the above hypertension of moderate, the severe pulmonary insufficiency, the severe arrhythmia, serious primary disease such as liver, kidney and hemopoietic system, the psychotic.
Therapeutic Method: oral liquid of the present invention 20ml/ time of treatment group, 3 times/d, 14 days was 1 course of treatment.Matched group is taken sorbitrate 10mg/ time, and 3 times/d, aspirin 100mg/ time, 1 time/d, 14 days was 1 course of treatment.Sublingual administration nitroglycerin temporarily during patient's angina pectoris attacks during the treatment, but all must not add nitrate esters, calcium antagonist and beta-blocker again.
Curative effect determinate standard: " the clinical research guideline of the new Chinese medicine treatment thoracic obstruction (angina pectoris) " that " angina pectoris and ECG curative effect evaluation criteria " that the national prevention and treatment in Chinese and western angina pectoris arrhythmia research forum of reference is formulated and Ministry of Public Health are formulated and issued.
Clinical efficacy behind two groups of patient treatments
The progress of group produce effects is invalid
Treatment organizes 15 12 2
Matched group 10 14 6
Two kinds of Therapeutic Method are to Electrocardiographic improvement situation
The progress of group produce effects is invalid
Treatment organizes 9 12 2
Matched group 6 10 14
Concrete embodiment:
Embodiments of the invention 1:
Herba Erigerontis 990g, Semen Ginkgo 10g
Get Herba Erigerontis, decoct with water 1 time, each 0.5 hour, merge decocting liquid, filter concentrating under reduced pressure, add ethanol precipitation, leave standstill, supernatant decompression recycling ethanol 6N HCl is adjusted to pH about 2.5, extract with ethyl acetate-ethanol (9: 1) mixed solution, the extract concentrating under reduced pressure is removed ethyl acetate, drying, be ground into the above fine powder of 60 orders, promptly get Herba Erigerontis extract; Get Semen Ginkgo, be ground into coarse powder, make solvent with 70% ethanol, reflux, extract, 1 time after each 1 hour, reclaims ethanol, add water dissolution, refining with macroporous adsorbent resin, use 70% ethanol elution, collect effluent to colourless, effluent is through decompression recycling ethanol, concentrate, dry, pulverize, with the Herba Erigerontis extract mix homogeneously, add 2% methylcellulose again, add the moistening back of water and granulate, mixing incapsulates, and promptly gets capsule.This product oral, three times on the one, each 2.
Embodiments of the invention 2:
Herba Erigerontis 10g, Semen Ginkgo 990g
Get Herba Erigerontis, decoct with water 3 times, each 5 hours, merge decocting liquid, filter concentrating under reduced pressure, add ethanol precipitation, leave standstill, supernatant decompression recycling ethanol 6N HCl is adjusted to pH about 2.5, extract with ethyl acetate-ethanol (9: 1) mixed solution, the extract concentrating under reduced pressure is removed ethyl acetate, drying, be ground into the above fine powder of 60 orders, promptly get Herba Erigerontis extract; Get Semen Ginkgo, be ground into coarse powder, make solvent, reflux, extract, 3 times with 70% ethanol, after each 3 hours, reclaim ethanol, add water dissolution, refining with macroporous adsorbent resin, use 70% ethanol elution, collect effluent to colourless, effluent is through decompression recycling ethanol, and concentrated, dry, pulverizing add methylcellulose 2%, it is moistening to add water, makes granule, drying, add 3% carboxymethyl starch sodium, tabletting promptly gets tablet.
Embodiments of the invention 3:
Herba Erigerontis 500g, Semen Ginkgo 500g
Get Herba Erigerontis, decoct with water 2 times, each 3 hours, merge decocting liquid, filter concentrating under reduced pressure, add ethanol precipitation, leave standstill, supernatant decompression recycling ethanol 6N HCl is adjusted to pH about 2.5, extract with ethyl acetate-ethanol (9: 1) mixed solution, the extract concentrating under reduced pressure is removed ethyl acetate, drying, be ground into the above fine powder of 60 orders, promptly get Herba Erigerontis extract; Get Semen Ginkgo, be ground into coarse powder, make solvent with 70% ethanol, reflux, extract, 2 times after each 2 hours, reclaims ethanol, add water dissolution, refining with macroporous adsorbent resin, use 70% ethanol elution, collect effluent to colourless, effluent is through decompression recycling ethanol, concentrate, dry, pulverize, with the Herba Erigerontis extract mix homogeneously, add 2% low-substituted hydroxypropyl cellulose again, it is moistening to add water, make granule, drying promptly gets granule.
Embodiments of the invention 4:
Herba Erigerontis 800g, Semen Ginkgo 200g
Get Herba Erigerontis, decoct with water 3 times, each 5 hours, merge decocting liquid, filter concentrating under reduced pressure, add ethanol precipitation, leave standstill, supernatant decompression recycling ethanol 6N HCl is adjusted to pH about 2.5, extract with ethyl acetate-ethanol (9: 1) mixed solution, the extract concentrating under reduced pressure is removed ethyl acetate, drying, be ground into the above fine powder of 60 orders, promptly get Herba Erigerontis extract; Get Semen Ginkgo, be ground into coarse powder, make solvent with 70% ethanol, reflux, extract, 3 times is after each 3 hours, reclaim ethanol, add water dissolution, refining with macroporous adsorbent resin, use 70% ethanol elution, collect effluent to colourless, effluent is through decompression recycling ethanol, and concentrated, dry, pulverizing are again with the Herba Erigerontis extract mix homogeneously, add the dissolving of injection water, regulate pH value to 6.0～6.5 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled, filter, add an amount of sodium chloride for injection and make it dissolving; Add water for injection again to certain volume, filtration, fill, sterilization promptly get injection.
Embodiments of the invention 5:
Herba Erigerontis 200g, Semen Ginkgo 800g
Get Herba Erigerontis, decoct with water 1 time, each 0.5 hour, merge decocting liquid, filter concentrating under reduced pressure, add ethanol precipitation, leave standstill, supernatant decompression recycling ethanol 6N HCl is adjusted to pH about 2.5, extract with ethyl acetate-ethanol (9: 1) mixed solution, the extract concentrating under reduced pressure is removed ethyl acetate, drying, be ground into the above fine powder of 60 orders, promptly get Herba Erigerontis extract; Get Semen Ginkgo, be ground into coarse powder, make solvent with 70% ethanol, reflux, extract, 1 time is after each 1 hour, reclaim ethanol, add water dissolution, refining with macroporous adsorbent resin, use 70% ethanol elution, collect effluent to colourless, effluent is through decompression recycling ethanol, and concentrated, dry, pulverizing are again with the Herba Erigerontis extract mix homogeneously, add the dissolving of injection water, regulate pH value to 6.0～6.5 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled, filter, add an amount of sodium chloride for injection and make it dissolving; Add sterile water for injection to full dose, packing after vacuum lyophilization or aseptic filtration or the spray drying, sealing promptly gets injectable powder.
Claims (12)
1, a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease, it is characterized in that: calculate according to components by weight percent, it is mainly by 1～99 part of Herba Erigerontis, or corresponding the weight fraction Herba Erigerontis extract and 99～1 parts of Semen Ginkgoes that obtain after extracting, or the Semen Ginkgo extrac that corresponding weight fraction obtains after extraction is made.
2, according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: calculate according to components by weight percent, it is mainly by 20～80 parts of Herba Erigerontiss, or corresponding the weight fraction Herba Erigerontis extract and 80～20 parts of Semen Ginkgoes that obtain after extracting, or the Semen Ginkgo extrac that corresponding weight fraction obtains after extraction is made.
3, according to the Chinese medicine preparation of claim 1 or 2 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: calculate according to components by weight percent, it is by 50 parts of Herba Erigerontiss, or corresponding the weight fraction Herba Erigerontis extract and 50 parts of Semen Ginkgoes that obtain after extracting, or the Semen Ginkgo extrac that corresponding weight fraction obtains after extraction is made.
4, according to the Chinese medicine preparation of claim 1,2 or 3 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: described preparation is: injection, comprising: injection, powder pin, freeze-dried powder, tablet, capsule, soft capsule, pellet, granule, pill, powder, drop pill, slow releasing preparation, controlled release preparation, oral liquid, gel, soft extract, extractum and membrane.
5, according to the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 4, it is characterized in that: described preparation is: injection, comprising: injection, powder pin, freeze-dried powder, tablet, capsule, granule, drop pill, sustained-release preparation, membrane.
6, as the preparation method of the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 1-4, it is characterized in that: get Herba Erigerontis, decoct with water, merge decocting liquid, filter, concentrating under reduced pressure adds ethanol precipitation, leaves standstill, the clear liquid decompression recycling ethanol, re-refine, concentrate, crushed after being dried promptly gets Herba Erigerontis extract; Get Semen Ginkgo, be ground into coarse powder, alcohol reflux is collected extracting solution, reclaims ethanol, re-refine, concentrate, after the drying again with the Herba Erigerontis extract mix homogeneously, make different preparations then respectively.
7, according to the preparation method of the Chinese medicine preparation of the described treatment cardiovascular and cerebrovascular disease of claim 6, it is characterized in that: get Herba Erigerontis, decoct with water 1～3 time, each 0.5～5 hour, merge decocting liquid, filter, concentrating under reduced pressure adds ethanol precipitation, leave standstill, supernatant decompression recycling ethanol 6N HCl is adjusted to about pH2.5, with the extraction of ethyl acetate-ethanol (9: 1) mixed solution, extract concentrating under reduced pressure, remove ethyl acetate, drying is ground into the above fine powder of 60 orders, promptly gets Herba Erigerontis extract; Get Semen Ginkgo, be ground into coarse powder, make solvent with 70% ethanol, reflux, extract, 1～3 time after each 1～3 hour, reclaims ethanol, add water dissolution, refining with macroporous adsorbent resin, use 70% ethanol elution, collect effluent to colourless, effluent is through decompression recycling ethanol, concentrated, dry, pulverizing again with the Herba Erigerontis extract mix homogeneously, are made different preparations respectively then.
8, according to the preparation method of the Chinese medicine preparation of claim 6 or 7 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add 2% methylcellulose, adding the moistening back of water granulates, drying incapsulates, and promptly gets capsule preparations.
9, according to the preparation method of the Chinese medicine preparation of claim 6 or 7 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add methylcellulose 2%, it is moistening to add water, make granule, drying adds 3% carboxymethyl starch sodium, tabletting promptly gets tablet.
10, according to the preparation method of the Chinese medicine preparation of claim 6 or 7 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add 2% low-substituted hydroxypropyl cellulose, it is moistening to add water, make granule, drying promptly gets granule.
11, according to the preparation method of the Chinese medicine preparation of claim 6 or 7 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add the dissolving of injection water, regulate pH value to 6.0～6.5 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled filters, and adds an amount of sodium chloride for injection and makes it dissolving; Add water for injection again to certain volume, filtration, fill, sterilization promptly get injection.
12, according to the preparation method of the Chinese medicine preparation of claim 6 or 7 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: get Herba Erigerontis extract, Semen Ginkgo fine powder or extract and mix evenly, add the dissolving of injection water, regulate pH value to 6.0～6.5 with 10% sodium hydroxide solution, add injection water and 0.1% needle-use activated carbon, the mixed solution heated and boiled filters, and adds an amount of sodium chloride for injection and makes it dissolving; Add sterile water for injection to full dose, packing after vacuum lyophilization or aseptic filtration or the spray drying, sealing promptly gets injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022510 CN1569158A (en) | 2004-05-10 | 2004-05-10 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022510 CN1569158A (en) | 2004-05-10 | 2004-05-10 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1569158A true CN1569158A (en) | 2005-01-26 |
Family
ID=34480169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410022510 Pending CN1569158A (en) | 2004-05-10 | 2004-05-10 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1569158A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104739913A (en) * | 2015-03-26 | 2015-07-01 | 鼎旺生物科技有限公司 | Preparation for accelerating wound healing, and preparation method and application thereof |
-
2004
- 2004-05-10 CN CN 200410022510 patent/CN1569158A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104739913A (en) * | 2015-03-26 | 2015-07-01 | 鼎旺生物科技有限公司 | Preparation for accelerating wound healing, and preparation method and application thereof |
| CN104739913B (en) * | 2015-03-26 | 2018-06-01 | 鼎旺生物科技有限公司 | A kind of preparation for accelerating wound healing, preparation method and applications |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN1824177A (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN1462620A (en) | Powder of flenabane and its preparation method as well as application in making drugs | |
| CN1562186A (en) | Preparation of Chinese traditional medicine for curing Illness of Cardiac cerebral ischemia and preparation method | |
| CN100350899C (en) | Diphase capsule of red sage root for coronary heart disease and preparation method | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1569158A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1853689A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
| CN1857385A (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1593439A (en) | Orally disintegrating tablet of notoginsen total saponins and its preparation | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1310635C (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1907315A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1762417A (en) | Compound formulation of astragalus root for treating cardiovascular and cerebrovascular diseases, its preparation process and use | |
| CN1686240A (en) | Coronary salvia micro pill agent and its preparation method | |
| CN1634255A (en) | Compound formulation of breviscapine for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1895314A (en) | Sanchi total saponin free-dried powdery injection against smash and its preparation | |
| CN1446554A (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1682821A (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN1543968A (en) | Drug prepared by mulberry bark extract | |
| CN1586553A (en) | Medicinal composition for treating cardiocerebral vascular disease and its preparing method | |
| CN1596954A (en) | Red ginseng and ophiopogon root preparation and its making method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |